Johnson & Johnson's Nipocalimab Shows Stronger Response in Sjögren's Patients with High Autoantibody Levels

Event summary

  • Johnson & Johnson presented new biomarker data from the Phase 2 DAHLIAS study, showing that nipocalimab achieved higher response rates (62.5%) in Sjögren's patients with elevated autoantibody levels compared to the overall population (51.9%).
  • The study, involving 163 adults with moderate-to-severe Sjögren's disease, demonstrated statistically significant improvements in ClinESSDAI scores with nipocalimab versus placebo.
  • Nipocalimab, an immunoselective FcRn blocker, is designed to reduce pathogenic IgG autoantibodies while preserving immune function.
  • The data will be presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress.
  • Nipocalimab has received both Breakthrough Therapy and Fast Track Designations from the U.S. FDA for Sjögren's disease.

The big picture

Johnson & Johnson's nipocalimab represents a targeted approach to treating Sjögren's disease, a chronic autoimmune condition with significant unmet medical needs. The Phase 2 data reinforces the potential of FcRn blockers in reducing pathogenic autoantibodies while preserving immune function, positioning nipocalimab as a promising candidate in the autoimmune disease space. The strategic focus on biomarker-driven insights could differentiate nipocalimab in a competitive landscape, particularly as Johnson & Johnson seeks to address the systemic manifestations of Sjögren's disease.

What we're watching

Clinical Efficacy
How the Phase 3 DAFFODIL study will validate nipocalimab's efficacy in a broader Sjögren's patient population, particularly those with elevated autoantibody levels.
Regulatory Pathway
Whether the Breakthrough Therapy and Fast Track Designations will accelerate nipocalimab's approval process for Sjögren's disease.
Market Potential
The pace at which Johnson & Johnson can expand nipocalimab's indications into other autoantibody-driven diseases, leveraging its immunoselective mechanism.

Related topics

Pharmaceuticals Biotechnology